Clinical Trials Logo

Filter by:
NCT ID: NCT01894256 Active, not recruiting - Solid Tumours Clinical Trials

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function

Start date: November 2013
Phase: Phase 1
Study type: Interventional

This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate renal impairment compared to patients with normal renal function; Part B will allow eligible study patients continued access to olaparib after the PK phase and will provide additional safety data.

NCT ID: NCT01894139 Active, not recruiting - Obesity Clinical Trials

An Optimized Programming of Healthy Children (APPROACH)

Start date: January 4, 2014
Phase: N/A
Study type: Interventional

The Nutrition Research Unit at Copenhagen University Hospital Herlev will during the fall 2013 initiate a randomized and controlled intervention study engaging 390 obese pregnant women. The overall aim of APPROACH is to investigate how an optimal diet during pregnancy influences the programming of the offspring. The children will after birth be included in a prospective cohort according to maternal randomization and examined six times from delivery until the age of nine years.

NCT ID: NCT01887938 Active, not recruiting - Clinical trials for Metachromatic Leukodystrophy (MLD)

An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy

Start date: May 23, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to collect long-term safety data in participants with metachromatic leukodystrophy (MLD) who are receiving HGT-1110 and have participated in Study HGT-MLD-070 (NCT01510028) through Week 40.

NCT ID: NCT01879358 Active, not recruiting - Clinical trials for Coronary Artery Disease

Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent

SORT OUT VII
Start date: November 2012
Phase: N/A
Study type: Interventional

The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is to compare the safety and efficacy of the sirolimus eluting ORSIRO stent and the biolimus-eluting NOBORI stent in a population-based setting, using registry detection of clinically driven events

NCT ID: NCT01857414 Active, not recruiting - Clinical trials for Myocardial Reperfusion Injury

Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI

CONDI2
Start date: November 2013
Phase: N/A
Study type: Interventional

The aim of the the study is to investigate whether Remote Ischaemic Conditioning (RIC) can improve clinical outcomes (cardiac death and hospitalisation for heart failure) at one year in patients presenting with ST-elevation Myocardial Infarction and undergoing primary percutaneous coronary intervention. This will be done in a multinational investigator-driven, multi-centre, randomised, controlled, single-blind, parallel assignment, prospective clinical efficacy trial.

NCT ID: NCT01853865 Active, not recruiting - Endometrial Cancer Clinical Trials

Follow-up of Endometrial Cancer Patients

OPAL
Start date: May 2013
Phase: N/A
Study type: Interventional

The present study is conducted, to elucidate the value of follow-up examinations in endometrial cancer patients. Specifically the objective is to compare hospital-based follow-up examinations with instruction in self-referral in stage I endometrial cancer patients. The investigators hypothesize that the intervention, instruction in self-referral, will: - reduce fear of recurrence - improve quality of life - improve cost-utility - not affect disease-free survival.

NCT ID: NCT01848561 Active, not recruiting - Clinical trials for Ulcerative Colitis (UC)

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Start date: April 29, 2013
Phase:
Study type: Observational

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

NCT ID: NCT01845259 Active, not recruiting - Clinical trials for Impaired Glucose Tolerance Associated With Drugs

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?

GREAT
Start date: April 2013
Phase: Phase 2
Study type: Interventional

Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among antipsychotic-treated patients. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances and can rarely be replaced by other drugs due to the effectiveness of the compounds. Glucagon-like peptide 1 (GLP-1) has improved glycemic control among patients with type 2 diabetes. The study will investigate whether the beneficial effects of GLP-1 analogues on glycemic control in type 2 diabetic patients, can be extended to a population of non-diabetic, dysglycemic psychiatric patients, receiving antipsychotic medical treatment.

NCT ID: NCT01844505 Active, not recruiting - Clinical trials for Unresectable or Metastatic Melanoma

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Start date: June 11, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.

NCT ID: NCT01843374 Active, not recruiting - Clinical trials for Unresectable Pleural or Peritoneal Malignant Mesothelioma

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Tremelimumab
Start date: May 17, 2013
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.